biossil is an AI native biopharma company based in Toronto.
It is advancing late-stage programs in life-threatening indications with urgent unmet needs.
Active trials are ongoing in Sickle Cell Disease, Idiopathic Pulmonary Fibrosis, Glioblastoma, Breast Cancer, and Alzheimer’s Disease.
This year additional trials will launch in Hereditary Xerocytosis, Cisplatin-Associated Nephrotoxicity, Basal Cell Carcinoma/Squamous Cell Carcinoma, MPS VI, GI-Acute Radiation Syndrome, and Premature Ovarian Failure.
Future clinical programs in development include Portal Hypertension, Radiation Dermatitis, Necrotizing Soft Tissue Infection, Vaso-Occlusive Crises and Diabetic Cardiomyopathy.
This work is supported by OpenAI and Founders Fund, among others. It is led by Alexander I. Mosa (MD PhD) and Anthony Mouchantaf (JD MBA).
For information about our trials, contact us at trials@biossil.ai. For partnership and licensing opportunities, contact us at partnerships@biossil.ai.
For peer-reviewed information about our pipeline, visit the links below:
Anderson, 2025 (a);
Anderson 2025 (b);
Anderson 2025 (c);
Pulliam, 2025;
Wagner 2024;
Walker 2024;
Uzomah, 2024;
Dunlap 2024;
Anderson, 2024;
Januzzi, 2024;
Yao, 2024;
Dampier, 2023;
Mosa, 2023;
Campo, 2023;
Tuyaa-Boutsugue, 2023;
Mapuskar, 2023;
Greco, 2023;
Gopal, 2023;
Hausmann, 2023;
Guffon, 2022;
Anderson, 2022;
Giralt, 2022;
Ataga, 2021;
Nayak, 2021;
Brakenridge, 2021;
Ko, 2021;
Hickerson, 2021;
Sisch, 2021;
Coyle, 2021;
Gopal, 2021;
Tammara, 2020;
Dampier, 2020;
Bulgar, 2020;
Mosa, 2020(a);
Mosa, 2020(b);
Entchev, 2020;
Jin, 2019;
Edgar, 2019;
Anderson, 2019;
Anderson, 2018;
Morikis, 2017;
Tammara, 2017;
Riviera, 2017;
Organ, 2017;
Telen, 2015;
Ramachandran, 2015;
Urowtiz, 2015;
Bulger, 2014;
Mirzoeva, 2014;
Sthoeger, 2013;
Chang, 2010;
Price, 2009;
Alper, 2008;
Sela, 2008;
Myers, 2008;
Elmann, 2007;
Upreti, 2006;
Toomey, 2006;
Arad, 2000.